0.388  0.001 (0.26%)		04-23 16:00
Open: 0.3851 High: 0.3899 Volume: 23,773		Pre. Close: 0.387 Low: 0.38 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	0.51	1-year :	0.55
Resists	First :	0.44	Second :	0.47
Pivot price	0.41
Supports	First :	0.37	Second :	0.31
MAs	MA(5) :	0.39	MA(20) :	0.41
	MA(100) :	0.43	MA(250) :	0.68
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	11.7	D(3) :	19.3
RSI	RSI(14): 40.6
52-week	High :	2.75	Low :	0.34

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SHPH ] has closed above bottom band by 11.9%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.39 - 0.39	0.39 - 0.39
Low:	0.38 - 0.38	0.38 - 0.38
Close:	0.38 - 0.39	0.39 - 0.39

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Wed, 03 Apr 2024
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024 - GlobeNewswire

Fri, 22 Mar 2024
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update - PR Newswire

Fri, 22 Mar 2024
Shuttle Pharma advances cancer treatment with FDA trial nod - Investing.com

Tue, 13 Feb 2024
Shuttle Pharmaceuticals Advances Prostate Cancer Diagnostics Funding - TipRanks.com - TipRanks

Tue, 13 Feb 2024
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering - PR Newswire

Tue, 06 Feb 2024
Shuttle Pharmaceuticals Acquires Promising Prostate Cancer Technology - TipRanks.com - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	17 (M)
Shares Float	10 (M)
Held by Insiders	45.1 (%)
Held by Institutions	2.1 (%)
Shares Short	66 (K)
Shares Short P.Month	51 (K)

EPS	-0.44
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-50.5 %
Return on Equity (ttm)	-112.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.35
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.89
PEG Ratio	0
Price to Book value	1.55
Price to Sales	0
Price to Cash Flow	-1.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.